Siyue Lou

#548 Binwen Road
Hangzhou, 310053, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

A review on molecular crosstalk: Bioactive polysaccharides and gut microbiota in type 2 diabetes-Pathways, signaling, and therapeutic translation.

A review on molecular crosstalk: Bioactive polysaccharides and gut microbiota in type 2 diabetes-Pathways, signaling, and therapeutic translation.

Journal: International journal of biological macromolecules

Published: December 28, 2025

The retinol-metabolizing enzyme DHRS3 coordinates antigen presentation, endothelial stability, and cholesterol metabolism to suppress hepatocellular carcinoma progression.

The retinol-metabolizing enzyme DHRS3 coordinates antigen presentation, endothelial stability, and cholesterol metabolism to suppress hepatocellular carcinoma progression.

Journal: The Journal of biological chemistry

Published: November 04, 2025

Unsupervised Hierarchical Symbolic Regression for Interpretable Property Modeling in Complex Multi-Variable Systems.

Unsupervised Hierarchical Symbolic Regression for Interpretable Property Modeling in Complex Multi-Variable Systems.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: October 23, 2025

Novel PI3Kδ inhibitor exerts antitumor activity in Burkitt lymphoma by inducing ROS-dependent apoptosis.

Novel PI3Kδ inhibitor exerts antitumor activity in Burkitt lymphoma by inducing ROS-dependent apoptosis.

Journal: Medical oncology (Northwood, London, England)

Published: April 03, 2025

Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system.

Real-world safety profile of elexacaftor/tezacaftor/ivacaftor: a disproportionality analysis using the U.S. FDA adverse event reporting system.

Journal: Frontiers in pharmacology

Published: November 20, 2024

Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases.

Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases.

Journal: Frontiers in pharmacology

Published: November 19, 2024

Safety evaluation of irinotecan: a real-world disproportionality analysis using FAERS and JADER databases during the time period 2004-2024.

Safety evaluation of irinotecan: a real-world disproportionality analysis using FAERS and JADER databases during the time period 2004-2024.

Journal: Frontiers in pharmacology

Published: October 24, 2024

A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases.

A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases.

Journal: BMC psychiatry

Published: August 11, 2024

Analysis of tirzepatide in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and sex-specific subgroups.

Analysis of tirzepatide in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and sex-specific subgroups.

Journal: Frontiers in pharmacology

Published: July 15, 2024

Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database.

Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database.

Journal: Frontiers in pharmacology

Published: November 15, 2023

From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis.

From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis.

Journal: Frontiers in pharmacology

Published: October 30, 2023

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database.

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database.

Journal: Frontiers in pharmacology

Published: October 12, 2023

Showing 1-12 of 22

Last Updated: 09/26/2026